Ionis Pharmaceuticals Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.88%.
Did IONS Beat Earnings? Q1 2025 Results
Ionis Pharmaceuticals delivered a stronger-than-expected first quarter for 2025, posting a net loss of $0.93 per share against a consensus estimate of $1.03, a 9.86% beat, while revenue of $132.00 million cleared analyst forecasts by 7.75% and grew 10.5% year-over-year. The headline numbers were powered by a 28% surge in commercial revenue to $76.00 million, fueled by expanding SPINRAZA royalties of $48.00 million, growing WAINUA royalties of $9.00 million as that therapy launched internationally, and the first meaningful contributions from newly approved TRYNGOLZA. Looking ahead, the company significantly raised its full-year 2025 guidance, now targeting revenue of $725.00 million to $750.00 million, well above the prior floor of $600.00 million, buoyed by a $280.00 million upfront payment from Ono Pharmaceutical for the sapablursen licensing deal. With a PDUFA date for donidalorsen set for August 21, 2025, and Phase 3 olezarsen data expected in the third quarter, Ionis is advancing toward what management describes as sustained positive cash flow.
- TRYNGOLZA launch generated first-ever direct product revenue of over $6 million in first full quarter
- SPINRAZA royalty revenue increased to $48 million from $38 million year-over-year
- WAINUA royalty revenue grew to $9 million from $1 million as global launches expanded
- Commercial revenue increased 28% year-over-year to $76 million
- Lower R&D expenses as several late-stage studies ended partially offset higher SG&A
“With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway. We look forward to continued momentum this year, including our second independent launch for donidalorsen in hereditary angioedema and Phase 3 results for olezarsen for severe hypertriglyceridemia in the third quarter. We also continue to advance our next wave of wholly owned neurology medicines, including ION582 for Angelman syndrome, which is on track to start Phase 3 development shortly. Our advancing pipeline of transformational medicines, together with strong commercial and financial execution, position Ionis to deliver increasing value for all stakeholders.”
Ionis Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Ionis raised its full-year 2025 financial guidance by more than 20%, reflecting strong Q1 results and the sapablursen licensing transaction. Revenue is now expected at $725-750 million (previously >$600 million). Non-GAAP operating loss is expected below $375 million (previously <$495 million). Year-end cash, cash equivalents and short-term investments expected at approximately $1.9 billion (previously ~$1.7 billion). The company anticipates four independent launches over the next two years, with donidalorsen (PDUFA August 21, 2025) as the next potential launch. Phase 3 data for olezarsen in severe hypertriglyceridemia expected in Q3 2025. The company expects to achieve sustained positive cash flow driven by growing product and royalty revenue coupled with disciplined investment.
IONS YoY Financials
IONS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.